文章：

子宫内膜癌分子靶点的临床可操作性

Clinical actionability of molecular targets in endometrial cancer

原文发布日期：2019-08-06

DOI: 10.1038/s41568-019-0177-x

类型: Review Article

开放获取: 否

英文摘要：

Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women’s health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.

摘要翻译： 

子宫内膜癌每年在全球导致约7.6万名女性死亡。该疾病的死亡率及新增病例数的持续增长，使其成为女性健康领域的重要议题，尤其在工业化国家——这类肿瘤发病率最高的地区表现尤为突出。绝大多数子宫内膜癌为癌瘤，其余则为肉瘤。子宫内膜癌可根据组织学亚型分为多种类别，包括子宫内膜样癌、浆液性癌和透明细胞癌。目前临床常规通过组织学分型指导子宫内膜癌患者的预后评估和治疗决策，同时现有研究正在评估分子分型的潜在临床应用价值。本综述将系统阐述子宫内膜癌的核心分子特征，并重点探讨近期关于特定分子特征在早期检测、疾病风险分层及靶向治疗指导方面潜在临床应用价值的研究进展。

原文链接：

Clinical actionability of molecular targets in endometrial cancer